MOTS-c is a 16-amino-acid peptide encoded not in the nuclear genome but inside the mitochondrial 12S ribosomal RNA region, one of a small family of mitochondria-derived peptides that act as signaling molecules. Almost everything published about it so far comes from cell culture, animal models, or observational measurements in human blood, and two papers released this month show both why the field is interested and why it is nervous.

Retinal blood vessels in diabetic mice

A study in Cell Death Discovery by a Nanjing Drum Tower Hospital team reported that MOTS-c is predominantly localized in retinal endothelial cells, the lining that forms the blood-retinal barrier. The work was done in human retinal endothelial cells exposed to high glucose and in streptozotocin-induced diabetic mice, with no human trial involved.

In both systems, high glucose reduced MOTS-c expression in the retinal vasculature. When the researchers supplied the peptide back, they reported protection of the endothelial barrier and improvement of mitochondrial dysfunction in the cells, and rescue of vascular endothelial damage in the mice.

The enzyme doing the work

Transcriptomic and lipidomic profiling pointed to phospholipase A2 activity, and one gene, PLA2G6, showed the largest upregulation after MOTS-c treatment. The authors describe PLA2G6-mediated degradation of lipid peroxides as the primary mediator of the barrier protection they observed.

The cleanest part of the paper is the knockdown. With PLA2G6 removed, the protective effect collapsed both in vitro and in vivo, which is the kind of loss-of-function test a lot of peptide research skips.

A stress signal, not a tonic

A review in the Journal of Translational Medicine from Air Force Medical University and Xi'an Jiaotong University concludes that MOTS-c is a context-dependent signal whose effects shift with cell type, metabolic state, and inflammatory environment. It catalogs reported roles in exercise adaptation, insulin resistance models, endothelial protection, and inflammatory signaling, largely via AMPK activation and suppression of mTORC1.

The cancer section is the reason this matters. In some tumor models the review describes MOTS-c promoting apoptosis and chemotherapy sensitivity, while in others it describes the same peptide supporting tumor cell survival, remodeling the microenvironment, and possibly contributing to therapeutic resistance. The authors call that evidence emerging and still limited.

What Isn't Established

Human abundance data do not agree with themselves. The review notes that cohort studies have reported lower, elevated, and unchanged circulating MOTS-c in conditions such as type 2 diabetes, obesity, and coronary artery disease, and blames assay variability, the peptide's short half-life, age, sex, BMI, and circadian effects.

It also notes that circulating levels may not reflect the intracellular pools that actually matter, and calls for standardized detection methods before the relationship to human disease can be settled. On the eye work, the authors say delivery, dosing, stability, and long-term safety were not addressed, and that human diabetic retinas exposed to years of metabolic fluctuation may behave differently from acute experimental hyperglycemia.

Where the evidence stands

One defined molecular axis in mice and cells, and a review arguing against hype in either direction. The reviewers' own framing is the fairest summary available: MOTS-c is a stress signal, and what a stress signal does depends on who is listening.